Gilead Sciences presented the FDA Post-Marketing Pregnancy Study Requirements: Evaluating Study Reporting and Label Integration work during the Delivering Meaningful Answers in Clinical Decision-Making for Prenatal Exposures session at ISPE 42nd Annual Meeting in Milan.

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines